Abstract
BackgroundKaposi’s Sarcoma is the most common sarcoma and second most prevalent cancer seen in Tanzania. Little is known about Kaposi’s sarcoma in our setting as there is paucity of recent published data regarding this condition. This study describes the clinicopathological pattern and treatment outcome of Kaposi’s sarcoma at Bugando Medical Centre, a tertiary care hospital in northwestern Tanzania.MethodsThis was a prospective study of histologically confirmed Kaposi’s sarcoma that was conducted at Bugando Medical Center between July 2004 and June 2014.ResultsA total of 248 patients (M:F = 1.4:1) representing 2.4 % of all malignancies during the study period were enrolled into the study. The median age at presentation was 36 years. Females were younger than males (p = 0.04). Out of 248 patients, 122 (49.2 %) were HIV positive. Of these, 46 (37.7 %) were males and 76 (62.3 %) females. AIDS-related Kaposi’s sarcoma were younger than HIV negative Kaposi’s sarcoma patients (p = 0.011). Median duration of symptoms was 6 months. Kaposi’s sarcoma was the AIDS defining disease in 82 (67.2 %) patients while in the remaining 40 (32.8 %) it was diagnosed between 1 and 14 months after the initial diagnosis of AIDS. The lower limb was most frequently involved site in 28.9 % of patient. Females had more disseminated lesions compared with more localized lesions in the males (p = 0.001). The treatment modalities in this study included chemotherapy, radiotherapy, surgery and highly active antiretroviral therapy. Overall 126 (53.4 %) patients had significant improvement in quality of life at the end of 1 year follow up. Treatment related complication and mortality rates were 25.8 and 24.2 % respectively. Poor ACTG stage, CD4+ count <200 cells/µl, associated co-morbid illness, disseminated disease and poor adherent to chemotherapy were the significant independent factors associated with deaths (p < 0.001). Patient’s follow-up was generally poor and data on long-term survivals were not available as more than two-thirds of patients were lost to follow up.ConclusionKaposi’s sarcoma is the most common malignant vascular tumor and HIV/AIDS- related cancer in our region. There is an urgent need to develop health education programmes to enhance the understanding of this disease and how it spreads, particularly among the younger generation.
Highlights
Kaposi’s Sarcoma is the most common sarcoma and second most prevalent cancer seen in Tanzania
Kaposi’s sarcoma is the most common malignant vascular tumor and second most prevalent cancer seen in Tanzania and is commonly associated with human immunodeficiency virus (HIV)/acquired immunodeficiency states (AIDS) [21,22,23]
The proportion of patients with Kaposi’s sarcoma in Tanzania is not known and it was estimated at 50 %, and given 1.96 value of the 95 % confidence interval and 0.05 an acceptable margin of error, the minimum sample size required for the study was: n
Summary
Kaposi’s Sarcoma is the most common sarcoma and second most prevalent cancer seen in Tanzania. Kaposi’s sarcoma (KS) is a malignant neoplasm of the vascular endothelium that is multifocal in origin involving the skin and other organs [1]. It was first described in 1872 by Moritz Kaposi, a Hungarian dermatologist who described KS as a rare multifocal angioproliferative tumor involving blood and lymphatic vessels and it was thought to occur only in Eastern Europe and the Mediterranean [2, 3]. Kaposi’s sarcoma is the most frequently reported malignant skin tumor in some areas of Africa and was endemic in Africa even before the advent of the human immunodeficiency virus (HIV) [4, 5]. The course of Kaposi’s sarcoma ranges from indolent, with only skin manifestations to fulminant with extensive visceral involvement [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
